<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30938" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vaginal Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaltenecker</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>Campbell University Cape Fear Valley</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dunton</surname>
            <given-names>Charles J.</given-names>
          </name>
          <aff>Jefferson Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tikaria</surname>
            <given-names>Richa</given-names>
          </name>
          <aff>MSU</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Kaltenecker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Dunton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richa Tikaria declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30938.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The diagnosis of primary vaginal cancer is rare, comprising 1-2% of all female reproductive tract cancers because most lesions are metastatic, typically arising from other reproductive organs such as the cervix, endometrium, or ovary; however, they can also metastasize from distant sites such as the colon, breast, and pancreas. Primary vaginal cancer is strictly defined as a disease without evidence of cervical or vulvar cancer or a history of either within the past five years. When primary vaginal cancer is suspected, a biopsy is done for histopathologic confirmation. This activity reviews the background, diagnosis, treatment, and management of vaginal cancer and highlights the importance of proper knowledge and familiarity with this topic by the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the staging of vaginal cancer.</p></list-item><list-item><p>Implement recommended evaluation and staging processes for patients after biopsy-confirmed diagnoses of vaginal cancer.</p></list-item><list-item><p>Select optimal treatment options after vaginal cancer has been staged, including medical, surgical, and radiation oncology approaches.</p></list-item><list-item><p>Collaborate with the interprofessional team to plan coordinated treatment strategies to improve patient care and outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30938&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30938">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30938.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary vaginal cancer is rare,&#x000a0;comprising 1-2% of all female reproductive tract cancers.<xref ref-type="bibr" rid="article-30938.r1">[1]</xref>&#x000a0;The vagina is a 7&#x000a0;to 10-centimeter-long&#x000a0;fibromuscular tube extending from the cervix to the vulva, sitting posterior to the urethra and bladder&#x000a0;and anterior to the rectum.&#x000a0;It is divided into three parts, which are essential for classifying tumor location and lymphatic drainage. The lower third is below the level of the bladder base with the urethra anteriorly, the middle third is adjacent to the bladder base, and the upper third is at the level of the vaginal fornices, denoted as anterior, posterior, and lateral to the cervix.<xref ref-type="bibr" rid="article-30938.r2">[2]</xref></p>
        <p>Primary vaginal cancer is strictly defined as a disease without evidence of cervical or vulvar cancer or a history of&#x000a0;either within the past five years. Most vaginal lesions (80-90%) originate from cervical or vulvar lesions or other local sites such as the endometrium, bladder, rectosigmoid, or ovary. Distant sites of metastasis include the colon, breast, and pancreas. When primary vaginal cancer is suspected, a biopsy is done for histopathologic confirmation.<xref ref-type="bibr" rid="article-30938.r1">[1]</xref><xref ref-type="bibr" rid="article-30938.r3">[3]</xref></p>
        <p>While current estimates of vaginal cancer are higher than vulvar cancer, these estimates include primary and other genital lesions.<xref ref-type="bibr" rid="article-30938.r4">[4]</xref>&#x000a0;Currently, there are no randomized trials for the treatment of vaginal cancers due to the rarity of the disease, and guidelines are generally based on limited studies.<xref ref-type="bibr" rid="article-30938.r5">[5]</xref></p>
      </sec>
      <sec id="article-30938.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The pathways of carcinogenesis for vaginal cancer can be divided into human papillomavirus (HPV) induced&#x000a0;and&#x000a0;non-HPV induced.<xref ref-type="bibr" rid="article-30938.r6">[6]</xref>&#x000a0;As with cervical cancer, the HPV 16 virus strain accounts for most HPV-positive patients.<xref ref-type="bibr" rid="article-30938.r7">[7]</xref>&#x000a0;Within the HPV DNA, the activity of the viral reading frames E6 and E7 create proteins that interfere with critical cell cycle points. E6 interferes with suppressive tumor protein p53 and E7 with retinoblastoma protein (pRB). These are significant factors in HPV-related neoplasia, including primary vaginal cancer. The&#x000a0;E5 protein may also play a role in immune evasion.<xref ref-type="bibr" rid="article-30938.r8">[8]</xref></p>
        <p>Historically, diethylstilbestrol (DES), a synthetic estrogen used&#x000a0;to prevent miscarriages and preterm labor, has been associated with vaginal clear cell adenocarcinoma in offspring.<xref ref-type="bibr" rid="article-30938.r9">[9]</xref>&#x000a0;The incidence of this cancer has decreased since the routine use of DES was discontinued in the 1970s.</p>
      </sec>
      <sec id="article-30938.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Squamous cell carcinoma (SCC) of the vagina accounts for 90% of all patients with primary vaginal cancer, followed by adenocarcinoma, clear cell adenocarcinoma,&#x000a0;melanoma, sarcoma, and lymphoma of the vagina.<xref ref-type="bibr" rid="article-30938.r5">[5]</xref></p>
        <p>Invasive vaginal cancer shares many risk factors with cervical cancer, such as tobacco use, younger age&#x000a0;at first intercourse, HPV infection, and multiple sexual partners.<xref ref-type="bibr" rid="article-30938.r10">[10]</xref></p>
        <p>The incidence of vaginal cancer arising primarily from the vagina increases with age, with approximately 50% of patients presenting&#x000a0;over the age&#x000a0;of 70 years and 20%&#x000a0;over 80 years.<xref ref-type="bibr" rid="article-30938.r11">[11]</xref>&#x000a0;&#x000a0;Of these cancers,&#x000a0;SCC is by far the most common.<xref ref-type="bibr" rid="article-30938.r12">[12]</xref>&#x000a0;The average age of diagnosis is 67 years. Approximately 15% of women are diagnosed under&#x000a0;age 50; these are usually associated with cervical cancer.<xref ref-type="bibr" rid="article-30938.r5">[5]</xref></p>
        <p>Vaginal melanomas most likely&#x000a0;originate from mucosal melanocytes and most commonly present as vaginal bleeding in White women with a mean age of 60 years.<xref ref-type="bibr" rid="article-30938.r13">[13]</xref></p>
        <p>Verrucous carcinoma is a low-grade malignant variant of SCC and presents&#x000a0;as a large warty-appearing mass. This variant can be aggressive locally but is rarely metastatic.<xref ref-type="bibr" rid="article-30938.r14">[14]</xref>&#x000a0;</p>
        <p>While other sarcomas can arise in the vagina, the most common is embryonal rhabdomyosarcoma (ERMS) or sarcoma botryoides, a rare subtype of ERMS. These&#x000a0;occur in infants and young children, clinically appearing as soft nodular lesions.<xref ref-type="bibr" rid="article-30938.r15">[15]</xref></p>
      </sec>
      <sec id="article-30938.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Like the premalignant cervical lesions and carcinoma of the cervix, continual HPV infection, especially the HPV 16 subtype,&#x000a0;is associated with the long-term development of high-grade squamous intraepithelial lesions (HSIL) and carcinoma of the vagina. The squamous cells of the vaginal mucosa are similar to the cells of the ectocervix. Recently, the terminology for precancerous lesions has changed from vaginal intraepithelial lesion (VAIN) 1 to low-grade squamous intraepithelial lesion (LSIL) and VAIN 2-3 to high-grade squamous intraepithelial lesion (HGSIL). Because the vaginal epithelium does not&#x000a0;transform via squamous metaplasia, vaginal tissue less&#x000a0;commonly undergoes malignant transformation from HPV infection.</p>
        <p>Primary melanomas arising from the female reproductive system are uncommon and aggressive cancers. The vulva is the most frequent site (70%), followed by the vagina and, more rarely, the cervix.<xref ref-type="bibr" rid="article-30938.r16">[16]</xref>&#x000a0;Tumors that involve the vagina or cervix are strongly associated with high-risk clinicopathologic features, including increased tumor thickness, ulceration, positive surgical margins, lymph node metastasis, and poor long-term clinical outcomes, including death.<xref ref-type="bibr" rid="article-30938.r17">[17]</xref></p>
      </sec>
      <sec id="article-30938.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Approximately 90% of all primary vaginal cancers are SCC. Primary adenocarcinoma of the vagina is quite rare. DES-related clear cell carcinoma of the vagina occurred mainly in young women, but DES-related tumors are becoming rare as the DES-exposed cohort ages.<xref ref-type="bibr" rid="article-30938.r18">[18]</xref>&#x000a0;Histopathologic grades (G) are given to cancers to provide prognostic information about the tumor.</p>
        <list list-type="bullet">
          <list-item>
            <p>GX: Grade cannot be assessed</p>
          </list-item>
          <list-item>
            <p>G1: Well differentiated</p>
          </list-item>
          <list-item>
            <p>G2: Moderately differentiated</p>
          </list-item>
          <list-item>
            <p>G3: Poorly or undifferentiated</p>
          </list-item>
        </list>
        <p>Verrucous carcinoma histologically is composed of large papillary fronds covered by dense keratin. It has&#x000a0;relatively indistinct borders in the deep margins as opposed to the well-demarcated&#x000a0;borders of benign condyloma acuminate.<xref ref-type="bibr" rid="article-30938.r14">[14]</xref></p>
        <p>A small percentage of patients with vaginal cancer are diagnosed with sarcoma and melanoma. Primary vaginal melanoma is a rare mucosal neoplasm and is more aggressive than cutaneous melanoma.<xref ref-type="bibr" rid="article-30938.r19">[19]</xref></p>
      </sec>
      <sec id="article-30938.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In addition to a complete medical and surgical history, attention should&#x000a0;be given to any history of pelvic neoplasia or other malignancy. The most common presenting symptom of vaginal cancer is abnormal vaginal bleeding.<xref ref-type="bibr" rid="article-30938.r20">[20]</xref>&#x000a0;However, up to 20% of women may be asymptomatic and discovered on pelvic examination or with cytology for cervical cancer screening. Other&#x000a0;nondescript symptoms may be present, such as watery, malodorous, or blood-tinged vaginal discharge.<xref ref-type="bibr" rid="article-30938.r21">[21]</xref>&#x000a0;Patients may&#x000a0;report a vaginal mass, and local extension of&#x000a0;vaginal cancer can present&#x000a0;as urinary or gastrointestinal symptoms. Pelvic pain is often indicative of advanced disease. One of the most important aspects of the patient's history is the preexistence of cervical cancer. In a retrospective study, vaginal cancer was the most common metachronous malignancy&#x000a0;after a cervical cancer diagnosis.<xref ref-type="bibr" rid="article-30938.r22">[22]</xref>&#x000a0;</p>
        <p>Evaluation for suspected vaginal cancer requires a thorough physical exam, including a digital exam, a rectovaginal exam, a speculum exam, palpation of inguinal nodes, and colposcopy with biopsies. Visualizing the entire vagina by rotating the speculum to expose anterior and posterior surfaces is important. Applying&#x000a0;Lugol solution (iodine) during colposcopy can help visualize vaginal neoplasia.<xref ref-type="bibr" rid="article-30938.r23">[23]</xref></p>
        <p>It is also important to determine whether or not the patient has been appropriately vaccinated, as a reduction of vaginal neoplasia after HPV DNA vaccination has&#x000a0;been described.<xref ref-type="bibr" rid="article-30938.r24">[24]</xref></p>
      </sec>
      <sec id="article-30938.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There are no routine screening indications for vaginal cancer. If cervical cytology is abnormal and no cervical lesions are seen, evaluation for vaginal lesions should be undertaken. Vaginal cytology after hysterectomy for benign disease is not indicated due to low yield and high false positive rates. However, long-term surveillance is suggested after a hysterectomy for high-grade cervical intraepithelial neoplasia (CIN). This is especially true for immunologically compromised individuals.<xref ref-type="bibr" rid="article-30938.r25">[25]</xref><xref ref-type="bibr" rid="article-30938.r26">[26]</xref></p>
        <p>Low-grade VAIN does not require treatment and can be followed with cytology and colposcopy.<xref ref-type="bibr" rid="article-30938.r27">[27]</xref></p>
        <p>Biopsy remains the gold standard for diagnosing vaginal cancer. This can be best accomplished by an examination under anesthesia and should include inspection of the vaginal fornices and biopsies of the cervix. Clinical evaluation without anesthesia can also be performed if the patient is comfortable. Staging is&#x000a0;essential to developing a treatment plan if a primary invasive lesion is discovered. The current&#x000a0;staging systems include the International Federation of Gynecology and Obstetrics (FIGO) staging,&#x000a0;Tumor, Node, Metastasis (TNM) staging,&#x000a0;and the American Joint Commission on Cancer (AJCC) staging.<xref ref-type="bibr" rid="article-30938.r28">[28]</xref> Treatment planning may be modified based on imaging studies.</p>
        <p>Staging includes&#x000a0;data from the physical examination, cystoscopy, proctoscopy, and chest and skeletal radiography. Biopsy of lymph nodes may be included in the TNM staging, as well as data from a final resected specimen. No specific lab abnormalities exist&#x000a0;for diagnosing vaginal cancer; elevated liver function tests can suggest metastatic disease but are nonspecific.</p>
        <p>Magnetic resonance imaging (MRI) of the pelvis is useful in staging vulval and vaginal neoplasms to assess tumor size, local tumor extent, and the presence of lymph node metastases. Further indications for MRI are the diagnosis of post-therapeutic changes and tumor recurrence.<xref ref-type="bibr" rid="article-30938.r29">[29]</xref>&#x000a0;</p>
        <p>Although imaging studies have&#x000a0;limited utility in diagnosing vaginal cancer, FIGO encourages using computed tomography (CT), MRI, and positron emission tomography (PET), to guide therapy. However, the imaging findings may not&#x000a0;be used to change or reassign the stage.<xref ref-type="bibr" rid="article-30938.r30">[30]</xref>&#x000a0;In one study, FIGO evaluated the use of PET/CT to assess suspected or known disease (primary or recurrent). They reported a change in prognostic impression and intended patient management in 51% and 36% of studies performed, respectively.<xref ref-type="bibr" rid="article-30938.r31">[31]</xref></p>
        <p>It is essential to understand that&#x000a0;the vaginal lymphatic system is extensive. The middle to upper vagina drains with the cervical lymphatics into the pelvic obturator node, the internal and external iliac chains, and the para-aortic nodes. Of note, the inguinal nodes are the first drainage from the distal third of the vagina, then to the pelvic nodes. The posterior wall lymphatics drain with the rectal lymphatics.<xref ref-type="bibr" rid="article-30938.r32">[32]</xref></p>
      </sec>
      <sec id="article-30938.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Early vaginal cancers are generally treated with surgery or radiation therapy. Advanced cancers are treated with radiation therapy and the simultaneous administration of combined chemotherapy;&#x000a0;surgery has a limited role due to the proximity of the bladder, urethra, and rectum.<xref ref-type="bibr" rid="article-30938.r20">[20]</xref> It may be helpful in small stage I and II tumors or more extensive surgery in&#x000a0;patients with&#x000a0;a fistula from late-stage disease or recurrence after radiation.<xref ref-type="bibr" rid="article-30938.r33">[33]</xref></p>
        <p>Local excision may be possible for small (&#x0003c;2 cm) lesions confined to the mucosa.&#x000a0;For upper vaginal disease, radical hysterectomy (if the uterus is present) plus radical vaginectomy and pelvic lymphadenectomy is an option. For lower vaginal disease, radical excision&#x000a0;with groin node dissection is a treatment option. The goal for lower and upper disease is 1 cm disease-free margins.<xref ref-type="bibr" rid="article-30938.r34">[34]</xref>&#x000a0; Radical surgery for stage I and II cancers&#x000a0;has reported good outcomes; however, the series is small and retrospective.<xref ref-type="bibr" rid="article-30938.r35">[35]</xref> A literature review&#x000a0;reported that early-stage disease had a mean five-year survival rate of 77%.<xref ref-type="bibr" rid="article-30938.r12">[12]</xref>&#x000a0;Pelvic exenteration may be offered in central recurrences after radiation, but the significant risks and morbidity need to be addressed with the patient&#x000a0;before taking this approach. Palliative&#x000a0;surgery for fistulas may be necessary.<xref ref-type="bibr" rid="article-30938.r34">[34]</xref><xref ref-type="bibr" rid="article-30938.r36">[36]</xref></p>
        <p>A study from the National Cancer Database showed the use of combined chemoradiation therapy (CCRT) for patients with vaginal cancer has increased and is associated with a significant improvement. CCRT should be incorporated into treatment guidelines for vaginal cancer.<xref ref-type="bibr" rid="article-30938.r37">[37]</xref>&#x000a0;Enough success in treating cervical cancer with CCRT has moved the modality to vaginal cancer. Due to the rarity of vaginal cancer, data is limited for CCRT&#x000a0;compared&#x000a0;to&#x000a0;radiation therapy alone. However, a 2013 retrospective review of 71 patients demonstrated a disease-free and overall survival benefit from combined therapy.<xref ref-type="bibr" rid="article-30938.r38">[38]</xref>&#x000a0;Standard therapy for locally advanced vaginal cancer generally consists of combined external beam radiation therapy (EBRT) and brachytherapy, plus weekly cisplatin-based therapy.<xref ref-type="bibr" rid="article-30938.r39">[39]</xref><xref ref-type="bibr" rid="article-30938.r40">[40]</xref></p>
        <p>Vaginal melanoma is rare, and there is no standard treatment. Surgery for excision, including exenterative surgery, has been reported,&#x000a0;and there is limited evidence to support adjuvant therapy. The use of targeted therapy such as PD-L1 blockade has&#x000a0;increased and improved prognosis in cutaneous melanoma; however, vaginal melanoma has a different genetic profile with fewer BRAF mutations and more c-KIT mutations.<xref ref-type="bibr" rid="article-30938.r41">[41]</xref></p>
        <p>Individualized treatment of high-grade VAIN can prevent malignant conversion.&#x000a0;Reported&#x000a0;treatment modalities include laser&#x000a0;ablation, surgical excision, and topical treatments such as imiquimod and&#x000a0;topical chemotherapy with 5-fluorouracil.<xref ref-type="bibr" rid="article-30938.r27">[27]</xref></p>
      </sec>
      <sec id="article-30938.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for vaginal cancer is diverse and can include lesions not typical of the reproductive system. Sexually transmitted infections, such as herpes simplex and syphilis, can cause lesions that can mimic cancer. Vaginal trauma and atrophy can also present with bleeding similar to vaginal cancer. Benign vaginal masses include but are not limited to polyps, Gartner duct cysts, Bartholin gland cysts, and vaginal adenosis. From an oncologic perspective, cervical and vulvar cancer must be ruled out when determining if a lesion is a primary vaginal carcinoma. Metastatic lesions from the bladder and colorectal cancer have been reported.<xref ref-type="bibr" rid="article-30938.r42">[42]</xref></p>
      </sec>
      <sec id="article-30938.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgical management can be considered in stage I lesions that are amenable to hysterectomy with upper vaginectomy and lymph node dissection. Ideally, the lesions&#x000a0;will be&#x000a0;present in the apex of the posterior fornix of the vagina. Lower lesions can be approached with vulva-vaginectomy, but this procedure is uncommon due to its complex nature and associated complications.&#x000a0;For young women with vaginal cancer requiring radiation as primary treatment, ovarian transposition can be offered&#x000a0;before definitive radiation treatment to prevent the adverse effects of radiation-induced menopause. In selected patients, laparoscopic or extraperitoneal removal of bulky lymph nodes can be done as part of staging and treatment planning.<xref ref-type="bibr" rid="article-30938.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30938.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Radiation is the cornerstone of treatment for vaginal cancer, particularly in advanced stages.&#x000a0;It combines EBRT and intracavitary radiotherapy (ICRT) or brachytherapy. The principal advantage of radiation is organ preservation. The standard of care EBRT to the pelvis includes the external iliac and obturator nodes. Additionally, the inguinal nodes may be included if the tumor is in the distal vagina.<xref ref-type="bibr" rid="article-30938.r1">[1]</xref>&#x000a0;Careful treatment planning to cover the area of the tumor, the involved region(s), and the lymph nodes is essential for the best outcomes. Integration of CT and MRI has been shown to aid proper radiation treatment.<xref ref-type="bibr" rid="article-30938.r38">[38]</xref>&#x000a0;A dose&#x000a0;of&#x000a0;at least 70 Gy improves outcomes.<xref ref-type="bibr" rid="article-30938.r43">[43]</xref>&#x000a0;</p>
        <p>CCRT for patients with vaginal cancer has increased&#x000a0;and&#x000a0;has demonstrated significant improvement in survival in several studies.&#x000a0;In a National Cancer Database study of&#x000a0;13,689 patients, the median overall survival was 56.2 months with CCRT and 41.2 months with&#x000a0;radiation alone (p&#x0003c;0.0005).<xref ref-type="bibr" rid="article-30938.r37">[37]</xref></p>
        <p>Radiation treatment is contraindicated&#x000a0;in patients with verrucous carcinoma because it can provoke anaplastic transformation and worsen the prognosis.<xref ref-type="bibr" rid="article-30938.r14">[14]</xref></p>
      </sec>
      <sec id="article-30938.s13" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>&#x000a0;Due to its rarity, there are currently no randomized trials&#x000a0;regarding vaginal cancer treatment.</p>
      </sec>
      <sec id="article-30938.s14" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>In a review of 138 patients treated for vaginal cancer from the Korean Radiation Oncology Group, 12% had grade 3 or 4 acute toxicity, including skin, gastrointestinal, and genitourinary. Twelve patients (8%) showed late toxicity. The volume of the tumor and FIGO stage were foreboders of severe late toxicity. Ultimately, the data showed that a later stage of disease was associated with a worse survival outcome and more toxicity from treatment.<xref ref-type="bibr" rid="article-30938.r44">[44]</xref></p>
        <p>In extrapolation from radiotherapy for cervical cancer, vaginal toxicity from radiation for vaginal cancer includes the following:&#x000a0;dryness (18-21%), shortening (15-22%), tightening (16-22%),&#x000a0;dyspareunia (9-21%), and compromised enjoyment (37-47%). Hormone replacement therapy in this study showed significant improvement in alleviating symptoms.<xref ref-type="bibr" rid="article-30938.r45">[45]</xref></p>
        <p>Vaginal dilator therapy is recommended for women undergoing pelvic radiation to prevent vaginal stenosis; however, no standard protocols exist. A recent expert opinion suggests starting dilation around four weeks after treatment, using it 2&#x000a0;or 3 times per week for 1&#x000a0;to 3 minutes, and continuing it for up to a year. Using plastic dilators&#x000a0;of varying sizes had the best outcomes.<xref ref-type="bibr" rid="article-30938.r46">[46]</xref>&#x000a0;Literature suggests that a multidisciplinary clinic for sexual health may be beneficial after pelvic radiotherapy.<xref ref-type="bibr" rid="article-30938.r47">[47]</xref></p>
      </sec>
      <sec id="article-30938.s15" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>The use of chemotherapy in vaginal cancer is relatively new, and most research has been extrapolated from data on cervical cancer treatment. Treatment with cisplatin or 5-fluorouracil has demonstrated some efficacy.<xref ref-type="bibr" rid="article-30938.r48">[48]</xref>&#x000a0;Chemoradiation can be considered in the management plan of vaginal cancer following a recent retrospective review suggesting an encouraging improvement in overall and disease-free survival rates.<xref ref-type="bibr" rid="article-30938.r38">[38]</xref>&#x000a0;Although it was a small review of 71 patients, a significant difference was shown in overall survival and disease-free survival rates between women who received radiation alone versus those who received chemoradiation as initial treatment (three-year overall survival of 56% versus 79% and three-year disease-free survival of 43% versus 73%).<xref ref-type="bibr" rid="article-30938.r38">[38]</xref></p>
        <p>Limited studies&#x000a0;on chemotherapy for recurrent vaginal cancer are available. Benefits and toxicity should be carefully&#x000a0;considered when using systemic chemotherapy for these patients. Data on the use of chemotherapy is mainly from case reports. Cisplatin is the most common agent reported, and immunotherapy with&#x000a0;pembrolizumab and&#x000a0;nivolumab has been reported in a small number of patients. The poor prognosis for recurrent or stage IV disease may encourage further investigation of these agents.<xref ref-type="bibr" rid="article-30938.r5">[5]</xref></p>
      </sec>
      <sec id="article-30938.s16" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Staging (modified from American Cancer Society)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I- limited to the vaginal mucosa</p>
          </list-item>
          <list-item>
            <p>Stage II- involvement of the subvaginal tissue without extension to the pelvic sidewall</p>
          </list-item>
          <list-item>
            <p>Stage III- extension to the pelvic sidewall</p>
          </list-item>
          <list-item>
            <p>Stage IVA- spread to adjacent organs</p>
          </list-item>
          <list-item>
            <p>Stage IVB- spread to distant organs</p>
          </list-item>
        </list>
        <table-wrap id="article-30938.table0" position="float" orientation="portrait">
          <table style="width: 882px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">AJCC</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">TNM</td>
                <td style="width: 10px;" rowspan="1" colspan="1">FIGO</td>
                <td style="width: 626px;" rowspan="1" colspan="1">Description</td>
              </tr>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">IA</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">
<p>T1a</p>
<p>N0</p>
<p>M0</p>
</td>
                <td style="width: 10px;" rowspan="1" colspan="1">I</td>
                <td style="width: 626px;" rowspan="1" colspan="1">
<p>The cancer is&#x000a0;limited to the vagina and is no larger than 2.0 cm (T1a).</p>
<p>It does not involve lymph nodes (N0) or distant sites (M0).</p>
</td>
              </tr>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">IB</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">
<p>T1b</p>
<p>N0</p>
<p>MO</p>
</td>
                <td style="width: 10px;" rowspan="1" colspan="1">I</td>
                <td style="width: 626px;" rowspan="1" colspan="1">
<p>The cancer is limited to the vagina but is larger than 2.0 cm (T1b).</p>
<p>It does not involve lymph nodes (N0) or distant sites (M0).</p>
</td>
              </tr>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">IIA&#x000a0;</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">&#x000a0;
<p>T2a</p>
<p>N0</p>
<p>M0</p>
</td>
                <td style="width: 10px;" rowspan="1" colspan="1">&#x000a0;II</td>
                <td style="width: 626px;" rowspan="1" colspan="1">
<p>Cancer has spread to the connective tissues next to the vagina, but not as far as the pelvic wall, and is no larger than 2.0 cm (T2a).</p>
<p>It has not spread to nearby lymph nodes (N0) or distant sites (M0).</p>
</td>
              </tr>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">IIB&#x000a0;</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">
<p>T2b</p>
<p>N0</p>
<p>M0</p>
&#x000a0;</td>
                <td style="width: 10px;" rowspan="1" colspan="1">II&#x000a0;</td>
                <td style="width: 626px;" rowspan="1" colspan="1">
<p>Cancer has spread to the connective tissues next to the vagina, but not as far as the pelvic wall, but is larger than 2.0 cm (T2b).</p>
<p>It has not spread to nearby lymph nodes (N0) or distant sites (M0).</p>
</td>
              </tr>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">III&#x000a0;</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">&#x000a0;
<p>T1 to T3</p>
<p>N0/N1&#x000a0;</p>
<p>M0</p>
</td>
                <td style="width: 10px;" rowspan="1" colspan="1">&#x000a0;III</td>
                <td style="width: 626px;" rowspan="1" colspan="1">
<p>Cancer can be any size and has spread to the pelvic side wall and/or has caused hydronephrosis (T1 to T3).</p>
<p>It has also spread to nearby lymph nodes in the pelvis or groin (inguinal) area (N1) but not distant sites (M0). It may also be N0.</p>
</td>
              </tr>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">IVA&#x000a0;</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">&#x000a0;
<p>T4</p>
<p>Any N</p>
<p>M0</p>
</td>
                <td style="width: 10px;" rowspan="1" colspan="1">&#x000a0;IVA</td>
                <td style="width: 626px;" rowspan="1" colspan="1">
<p>Cancer involves&#x000a0;the bladder or rectum or is&#x000a0;present out of the pelvis (T4).&#x000a0;</p>
<p>It might or might not have spread to pelvic or inguinal lymph nodes (any N). It has not spread to distant sites (M0).</p>
</td>
              </tr>
              <tr>
                <td style="width: 27px;" rowspan="1" colspan="1">&#x000a0;IVB</td>
                <td style="width: 54.6719px;" rowspan="1" colspan="1">
<p>Any T</p>
<p>Any N&#x000a0;</p>
<p>M1</p>
</td>
                <td style="width: 10px;" rowspan="1" colspan="1">&#x000a0;IVB</td>
                <td style="width: 626px;" rowspan="1" colspan="1">
<p>Cancer can be any size and has spread to distant organs (lung, liver, bone) M1. It may invade adjacent organs.&#x000a0;</p>
<p>It might or might not have spread to pelvic or inguinal lymph nodes (any N).&#x000a0;</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>In a recent study of 124 patients, data revealed the following distribution: Stage I - 31%, Stage II - 36%, Stage III - 16%, and Stage IV - 17%.<xref ref-type="bibr" rid="article-30938.r49">[49]</xref></p>
      </sec>
      <sec id="article-30938.s17" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Many prognostic factors can influence the management plan. Lymph node metastasis is an important prognostic factor. Other factors include histology, size, and the patient's age. In a Surveillance, Epidemiology, and End Results (SEER) analysis of more than 2000 patients, the five-year disease-specific survival was 84% for stage I, 75% for stage II, and 57% for advanced tumors.<xref ref-type="bibr" rid="article-30938.r20">[20]</xref></p>
      </sec>
      <sec id="article-30938.s18" sec-type="Complications">
        <title>Complications</title>
        <p>Complications from the treatment of vaginal cancer depend on many factors&#x000a0;and can be divided into treatment-based and patient-based. Treatment-based factors include radiation intensity, type of surgery, and type of chemotherapy. Patient-based factors&#x000a0;include age, hormonal status, and personal hygiene. The complications from radiation include edema, erythema, and mucositis with or without ulceration. Usually, these effects resolve within a few months after treatment. See the Toxicity and Side Effect Management section.</p>
      </sec>
      <sec id="article-30938.s19" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>A cross-sectional survey of outpatient visits showed female&#x000a0;patients with cancer have unmet sexual and vaginal&#x000a0;health needs. Preferences for receiving sexual health information vary by age. Improved physician-patient communication, awareness, and educational resources using proven sexual health promotion strategies can help women cope with treatment side effects.<xref ref-type="bibr" rid="article-30938.r50">[50]</xref></p>
      </sec>
      <sec id="article-30938.s20" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Gynecologic cancers require an interprofessional team-based approach, especially in&#x000a0;patients with a rare disease such as vaginal cancer. Once the diagnosis is made, coordinated care should include the involvement of social workers, nurse navigators, radiation oncologists, and gynecologic oncologists.<xref ref-type="bibr" rid="article-30938.r20">[20]</xref></p>
        <p>Ideally, vaginal cancer should be reviewed at case-based&#x000a0;conferences.&#x000a0;Interprofessional team members&#x000a0;can include gynecologic oncology, plastic surgery, urology, radiation oncology, and operations staff. It is essential to coordinate with outpatient nurses, clinical nurse specialists, physician assistants, administrative assistants, physical medicine and rehabilitation specialists, social workers, sexual counselors, and the cancer survivorship practice.<xref ref-type="bibr" rid="article-30938.r51">[51]</xref></p>
        <p>Clinical nurse specialists assist the team by providing&#x000a0;psychological support to&#x000a0;the patients living with cancer and their caregivers.<xref ref-type="bibr" rid="article-30938.r52">[52]</xref>&#x000a0;Their role in&#x000a0;interprofessional&#x000a0;care has contributed successfully where medical factors (complex comorbidities) or non-medical factors (patient preference) impact treatment.<xref ref-type="bibr" rid="article-30938.r53">[53]</xref>&#x000a0;Nurses will assist in the evaluation and can assist during surgical procedures. They can also coordinate activities between different specialists and counsel patients. When chemotherapy is part of the treatment regimen, specialized oncology pharmacists will be a valuable asset to the team, helping to direct agent selection and dosing, performing medication reconciliation, and counseling patients on what to expect from their medication regimen.</p>
        <p>The issue of sexuality and sexual dysfunction is important, especially with treatment for vaginal cancer. Both physical and psychological issues need to be addressed; common&#x000a0;patient complaints include lack of sexual desire, dyspareunia, decreased sensation in the genital area, and&#x000a0;the inability to achieve orgasm.<xref ref-type="bibr" rid="article-30938.r54">[54]</xref>&#x000a0;An interprofessional approach focusing on the physical and psychosexual aspects of sexuality is needed to treat sexual difficulties effectively.<xref ref-type="bibr" rid="article-30938.r55">[55]</xref></p>
        <p>Pain management during and after therapy is essential, especially&#x000a0;in light of the current opioid crisis. Communication&#x000a0;about pain in patients with vaginal cancer&#x000a0;should be tailored to the individual patient experience.<xref ref-type="bibr" rid="article-30938.r56">[56]</xref>&#x000a0;Here again, pharmacists and nurses can make significant contributions to patient care.</p>
        <p>All care team members must maintain meticulous records so that everyone on the interprofessional team has the latest and most accurate information for patient decisions as a part of team communication. The interprofessional approach to care will yield optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-30938.s21">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30938&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30938">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/vaginal-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30938">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30938/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30938">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30938.s22">
        <title>References</title>
        <ref id="article-30938.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Cuello</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cancer of the vagina.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>143 Suppl 2</volume>
            <fpage>14</fpage>
            <page-range>14-21</page-range>
            <pub-id pub-id-type="pmid">30306589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gardner</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Sunil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klopp</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Sagebiel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhosale</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Primary vaginal cancer: role of MRI in diagnosis, staging and treatment.</article-title>
            <source>Br J Radiol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>88</volume>
            <issue>1052</issue>
            <fpage>20150033</fpage>
            <pub-id pub-id-type="pmid">25966291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>QJ</given-names>
              </name>
              <name>
                <surname>Namuduri</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Yam</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Lim-Tan</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Vaginal metastasis presenting as postmenopausal bleeding.</article-title>
            <source>Singapore Med J</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>8</issue>
            <fpage>e134</fpage>
            <page-range>e134-6</page-range>
            <pub-id pub-id-type="pmid">26311914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2022.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-33</page-range>
            <pub-id pub-id-type="pmid">35020204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulkarni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dogra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zigras</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Innovations in the Management of Vaginal Cancer.</article-title>
            <source>Curr Oncol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>27</day>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>3082</fpage>
            <page-range>3082-3092</page-range>
            <pub-id pub-id-type="pmid">35621640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Segev</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mackuli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Auslender</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lavie</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute.</article-title>
            <source>Isr Med Assoc J</source>
            <year>2016</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>286</fpage>
            <page-range>286-9</page-range>
            <pub-id pub-id-type="pmid">27430086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Backes</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hoots</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Kurman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Pimenta</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.</article-title>
            <source>Obstet Gynecol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>113</volume>
            <issue>4</issue>
            <fpage>917</fpage>
            <page-range>917-924</page-range>
            <pub-id pub-id-type="pmid">19305339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Har&#x00119;&#x0017c;a</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wilczy&#x00144;ski</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Paradowska</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Feb</month>
            <day>05</day>
            <volume>23</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">35163748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conlon</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Diethylstilbestrol: Potential health risks for women exposed in utero and their offspring.</article-title>
            <source>JAAPA</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>49</fpage>
            <page-range>49-52</page-range>
            <pub-id pub-id-type="pmid">28098674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daling</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Madeleine</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Shera</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McKnight</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Galloway</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>McDougall</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Tamimi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A population-based study of squamous cell vaginal cancer: HPV and cofactors.</article-title>
            <source>Gynecol Oncol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-70</page-range>
            <pub-id pub-id-type="pmid">11812085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Creasman</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Menck</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>The National Cancer Data Base report on cancer of the vagina.</article-title>
            <source>Cancer</source>
            <year>1998</year>
            <month>Sep</month>
            <day>01</day>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>1033</fpage>
            <page-range>1033-40</page-range>
            <pub-id pub-id-type="pmid">9731908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Goff</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CI</given-names>
              </name>
            </person-group>
            <article-title>Factors affecting risk of mortality in women with vaginal cancer.</article-title>
            <source>Obstet Gynecol</source>
            <year>2009</year>
            <month>May</month>
            <volume>113</volume>
            <issue>5</issue>
            <fpage>1038</fpage>
            <page-range>1038-1045</page-range>
            <pub-id pub-id-type="pmid">19384118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frumovitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Etchepareborda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Eifel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Levenback</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Primary malignant melanoma of the vagina.</article-title>
            <source>Obstet Gynecol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>1358</fpage>
            <page-range>1358-1365</page-range>
            <pub-id pub-id-type="pmid">21099603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramzy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Smout</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Verrucous carcinoma of the vagina.</article-title>
            <source>Am J Clin Pathol</source>
            <year>1976</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>644</fpage>
            <page-range>644-53</page-range>
            <pub-id pub-id-type="pmid">16535806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghaemmaghami</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Karimi Zarchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghasemi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lower genital tract rhabdomyosarcoma: case series and literature review.</article-title>
            <source>Arch Gynecol Obstet</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>278</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-9</page-range>
            <pub-id pub-id-type="pmid">18427824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gadducci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carinelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guerrieri</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Aletti</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Melanoma of the lower genital tract: Prognostic factors and treatment modalities.</article-title>
            <source>Gynecol Oncol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>180</fpage>
            <page-range>180-189</page-range>
            <pub-id pub-id-type="pmid">29728261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Udager</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Frisch</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Stasenko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Fullen</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Orsini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Gynecologic melanomas: A clinicopathologic and molecular analysis.</article-title>
            <source>Gynecol Oncol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>147</volume>
            <issue>2</issue>
            <fpage>351</fpage>
            <page-range>351-357</page-range>
            <pub-id pub-id-type="pmid">28844540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hacker</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Eifel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cancer of the vagina.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>131 Suppl 2</volume>
            <fpage>S84</fpage>
            <page-range>S84-7</page-range>
            <pub-id pub-id-type="pmid">26433679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Kok</surname>
                <given-names>VC</given-names>
              </name>
            </person-group>
            <article-title>Primary Vaginal Melanoma With Rhabdoid Features: A Case Report and Literature Review.</article-title>
            <source>Int J Gynecol Pathol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>499</fpage>
            <page-range>499-504</page-range>
            <pub-id pub-id-type="pmid">28800579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shrivastava</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Management of Vaginal Cancer.</article-title>
            <source>Rev Recent Clin Trials</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-97</page-range>
            <pub-id pub-id-type="pmid">26411952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiniker</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kapp</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes.</article-title>
            <source>Gynecol Oncol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>131</volume>
            <issue>2</issue>
            <fpage>380</fpage>
            <page-range>380-5</page-range>
            <pub-id pub-id-type="pmid">23954572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blake</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Machida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mandelbaum</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis.</article-title>
            <source>Gynecol Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>150</volume>
            <issue>3</issue>
            <fpage>501</fpage>
            <page-range>501-508</page-range>
            <pub-id pub-id-type="pmid">30054103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Indraccolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Baldoni</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A simplified classification for describing colposcopic vaginal patterns.</article-title>
            <source>J Low Genit Tract Dis</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-9</page-range>
            <pub-id pub-id-type="pmid">22227840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nyg&#x000e5;rd</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway.</article-title>
            <source>BMJ Open</source>
            <year>2018</year>
            <month>Feb</month>
            <day>23</day>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>e019005</fpage>
            <pub-id pub-id-type="pmid">29476028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mbuyisa</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Khumalo</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Makhathini</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalance of abnormal vault cytology after hysterectomy for cervical intraepithelial neoplasia, Pietermaritzburg.</article-title>
            <source>S Afr Fam Pract (2004)</source>
            <year>2022</year>
            <month>Mar</month>
            <day>31</day>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e5</page-range>
            <pub-id pub-id-type="pmid">35384680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egemen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Guido</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Saraiya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saslow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wentzensen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>LC</given-names>
              </name>
              <collab>Enduring Consensus Cervical Cancer Screening and Management Committee</collab>
            </person-group>
            <article-title>Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available.</article-title>
            <source>J Low Genit Tract Dis</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-201</page-range>
            <pub-id pub-id-type="pmid">35763610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes and risk of recurrence among patients with vaginal intraepithelial neoplasia: a comprehensive analysis of 576 cases.</article-title>
            <source>J Gynecol Oncol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>e6</fpage>
            <pub-id pub-id-type="pmid">29185264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <collab>FIGO Committee on Gynecologic Oncology</collab>
            <article-title>Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>105</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-4</page-range>
            <pub-id pub-id-type="pmid">19322933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauth</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kimmig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Forsting</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Diagnosis of vulval and vaginal neoplasms with magnetic resonance imaging].</article-title>
            <source>Gynakol Geburtshilfliche Rundsch</source>
            <year>2007</year>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>226</fpage>
            <page-range>226-35</page-range>
            <pub-id pub-id-type="pmid">17914269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajaram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maheshwari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Staging for vaginal cancer.</article-title>
            <source>Best Pract Res Clin Obstet Gynaecol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>822</fpage>
            <page-range>822-32</page-range>
            <pub-id pub-id-type="pmid">25847318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Hricak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sonoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Benz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abu-Rustum</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Sala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.</article-title>
            <source>Gynecol Oncol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>140</volume>
            <issue>3</issue>
            <fpage>420</fpage>
            <page-range>420-4</page-range>
            <pub-id pub-id-type="pmid">26790773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhingran</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Updates in the treatment of vaginal cancer.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>344</fpage>
            <page-range>344-351</page-range>
            <pub-id pub-id-type="pmid">35256422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gadducci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabrini</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lanfredini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sergiampietri</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>211</fpage>
            <page-range>211-24</page-range>
            <pub-id pub-id-type="pmid">25476235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Cuello</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cancer of the vagina: 2021 update.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>155 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>19</fpage>
            <page-range>19-27</page-range>
            <pub-id pub-id-type="pmid">34669198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sekhon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bora</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bajracharya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rawal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1176</fpage>
            <page-range>1176-81</page-range>
            <pub-id pub-id-type="pmid">27327154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ganeshan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gopireddy</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bande</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhosale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lall</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Current update on vaginal malignancies.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>11</issue>
            <fpage>5353</fpage>
            <page-range>5353-5368</page-range>
            <pub-id pub-id-type="pmid">34338815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sukumvanich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krivak</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Beriwal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study.</article-title>
            <source>Gynecol Oncol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>135</volume>
            <issue>3</issue>
            <fpage>495</fpage>
            <page-range>495-502</page-range>
            <pub-id pub-id-type="pmid">25281493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyamoto</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Concurrent chemoradiation for vaginal cancer.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>e65048</fpage>
            <pub-id pub-id-type="pmid">23762284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy Plus Chemotherapy Is Associated With Improved Survival Compared to Radiotherapy Alone in Patients With Primary Vaginal Carcinoma: A Retrospective SEER Study.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>570933</fpage>
            <pub-id pub-id-type="pmid">33392073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Donato</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bellati</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fischetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perniola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panici</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Vaginal cancer.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>286</fpage>
            <page-range>286-95</page-range>
            <pub-id pub-id-type="pmid">21571543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobric&#x00103;</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>V&#x000e2;j&#x000e2;itu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Condrat</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Cre&#x0021b;oiu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Popa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gaspar</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Suciu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cre&#x0021b;oiu</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Varlas</surname>
                <given-names>VN</given-names>
              </name>
            </person-group>
            <article-title>Vulvar and Vaginal Melanomas-The Darker Shades of Gynecological Cancers.</article-title>
            <source>Biomedicines</source>
            <year>2021</year>
            <month>Jun</month>
            <day>30</day>
            <volume>9</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34209084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Vaginal metastases from colorectal cancer.</article-title>
            <source>Int J Surg</source>
            <year>2013</year>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>1048</fpage>
            <page-range>1048-55</page-range>
            <pub-id pub-id-type="pmid">24076094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkbride</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fyles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rawlings</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Manchul</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Simm</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989).</article-title>
            <source>Gynecol Oncol</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>435</fpage>
            <page-range>435-43</page-range>
            <pub-id pub-id-type="pmid">7705681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>WI</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09).</article-title>
            <source>J Gynecol Oncol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>e17</fpage>
            <pub-id pub-id-type="pmid">26768782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirchheiner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>J&#x000fc;rgenliemk-Schulz</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Haie-Meder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chargari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lindegaard</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fokdal</surname>
                <given-names>LU</given-names>
              </name>
              <name>
                <surname>Spampinato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Sturdza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahantshetty</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Segedin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bruheim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Van der Steen-Banasik</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wiebe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sundset</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Limbergen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Villafranca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Westerveld</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>P&#x000f6;tter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tanderup</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nout</surname>
                <given-names>RA</given-names>
              </name>
              <collab>EMBRACE Collaborative Group</collab>
            </person-group>
            <article-title>Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>112</volume>
            <issue>2</issue>
            <fpage>400</fpage>
            <page-range>400-413</page-range>
            <pub-id pub-id-type="pmid">34478833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakker</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>ter Kuile</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Nout</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mens</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van Doorn</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>de Kroon</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hompus</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Braat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Creutzberg</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>1499</fpage>
            <page-range>1499-506</page-range>
            <pub-id pub-id-type="pmid">25248115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>D'Addario</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tymon-Rosario</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menderes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Johung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Minkin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Damast</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Benefits of a Multidisciplinary Women's Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>143</fpage>
            <page-range>143-149</page-range>
            <pub-id pub-id-type="pmid">33755031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kirwan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tierney</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Symonds</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fresco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Collingwood</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Sep</month>
            <day>08</day>
            <volume>358</volume>
            <issue>9284</issue>
            <fpage>781</fpage>
            <page-range>781-6</page-range>
            <pub-id pub-id-type="pmid">11564482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delara</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magrina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Magtibay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Langstraat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dinh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karlin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management and outcomes of primary vaginal Cancer.</article-title>
            <source>Gynecol Oncol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>159</volume>
            <issue>2</issue>
            <fpage>456</fpage>
            <page-range>456-463</page-range>
            <pub-id pub-id-type="pmid">32972784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stabile</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baser</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Goldfrank</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Abu-Rustum</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Barakat</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Dickler</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sexual health needs and educational intervention preferences for women with cancer.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>165</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">28547655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cook</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Recoche</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>"Our nurse is the glue for our team" - Multidisciplinary team members' experiences and perceptions of the gynaecological oncology specialist nurse role.</article-title>
            <source>Eur J Oncol Nurs</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>41</volume>
            <fpage>7</fpage>
            <page-range>7-15</page-range>
            <pub-id pub-id-type="pmid">31358260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McSorley</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the role of the clinical Nurse Specialist in cancer care: an integrative literature review.</article-title>
            <source>Eur J Cancer Care (Engl)</source>
            <year>2021</year>
            <month>May</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>e13415</fpage>
            <pub-id pub-id-type="pmid">33501707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raine</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The impact of Clinical Nurse Specialists on the decision making process in cancer multidisciplinary team meetings: A qualitative study.</article-title>
            <source>Eur J Oncol Nurs</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>43</volume>
            <fpage>101674</fpage>
            <pub-id pub-id-type="pmid">31689677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Sexuality and Menopause: Unique Issues in Gynecologic Cancer.</article-title>
            <source>Semin Oncol Nurs</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-216</page-range>
            <pub-id pub-id-type="pmid">30871843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gr&#x000e9;nman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Psychosexual health in gynecologic cancer.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>143 Suppl 2</volume>
            <fpage>147</fpage>
            <page-range>147-152</page-range>
            <pub-id pub-id-type="pmid">30306581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30938.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurtin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fuoto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pain Management in the Cancer Survivor.</article-title>
            <source>Semin Oncol Nurs</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>284</fpage>
            <page-range>284-290</page-range>
            <pub-id pub-id-type="pmid">31053398</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
